Latest Novartis Stories
- Farydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD1 EAST HANOVER, N.J., Feb.
As Syngenta Lawsuit Filing Continue Wright & Schulte LLC Is Holding A Series of Public Meetings To Provide Important Legal Information to Ohio Farmers Who May Have Incurred Significant Financial
RnRMarketResearch.com adds "Acute Heart Failure - Pipeline Review, H1 2015" report to its store.
- Decision could speed access to LCZ696 for heart failure with reduced ejection fraction patients in the US, reducing total review time from 12 to 8 months(1) EAST HANOVER, N.J., Feb.
NEW YORK, Feb.
BASEL, Switzerland, Feb. 13, 2015 /PRNewswire/ -- Syngenta announced that the 2014 Annual Report on Form 20-F has been filed with the U.S.
Solicam® herbicide will be marketed by the NovaSource® business unit of TKI PHOENIX, Feb. 11, 2015 /PRNewswire/ -- Tessenderlo Kerley, Inc.
Tapella & Eberspacher LLC, a leading Midwest personal injury law firm that handles cases throughout Illinois and Missouri, announced